226 related articles for article (PubMed ID: 35852077)
1. [The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs.].
Crisafulli S; Trifirò G
Recenti Prog Med; 2022; 113(7):425-429. PubMed ID: 35852077
[TBL] [Abstract][Full Text] [Related]
2. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
3. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
Crisafulli S; Sultana J; Ingrasciotta Y; Addis A; Cananzi P; Cavagna L; Conter V; D'Angelo G; Ferrajolo C; Mantovani L; Pastorello M; Scondotto S; Trifirò G
Expert Opin Drug Saf; 2019 Jun; 18(6):497-509. PubMed ID: 31059293
[TBL] [Abstract][Full Text] [Related]
4. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
5. Registries for orphan drugs: generating evidence or marketing tools?
Hollak CEM; Sirrs S; van den Berg S; van der Wel V; Langeveld M; Dekker H; Lachmann R; de Visser SJ
Orphanet J Rare Dis; 2020 Sep; 15(1):235. PubMed ID: 32883346
[TBL] [Abstract][Full Text] [Related]
6. [Harmonizing development, approval and access of drugs for rare diseases in Europe.].
Costa E; Magrini N
Recenti Prog Med; 2022; 113(7):407-410. PubMed ID: 35852074
[TBL] [Abstract][Full Text] [Related]
7. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
8. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
9. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
10. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
11. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
12. Traits, trends and hits of orphan drug designations in cystic fibrosis.
Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
[TBL] [Abstract][Full Text] [Related]
13. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
14. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
15. [Hope for patients with rare diseases--"orphan" drugs].
Kuzelová M; Kubácková K; Palágyi M; Smíd M
Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
[TBL] [Abstract][Full Text] [Related]
16. EU marketing authorization review of orphan and non-orphan drugs does not differ.
Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
[TBL] [Abstract][Full Text] [Related]
17. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
18. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Micallef J; Blin O
Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
[TBL] [Abstract][Full Text] [Related]
19. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
20. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
